tiprankstipranks
Argenx, Zai Lab Soar on Promising Data in CIDP
Market News

Argenx, Zai Lab Soar on Promising Data in CIDP

Shares of healthcare companies Argenx SE (NASDAQ:ARGX) and Zai Lab (NASDAQ:ZLAB) are on the rise today after the two partners announced positive topline data from a study (ADHERE) evaluating Vyvgart Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

Achieving its primary endpoint, the trial demonstrated a substantially lower risk of relapse with the drug versus placebo. Importantly, the promising results point to a meaningful improvement and stability in disease symptoms alongside a favorable safety profile.

Zai Lab is the exclusive licensee for the development and commercialization of the drug in the Greater China region and shares of the company are up nearly 8.6% today on the announcement of the data in CIDP.

Argenx shares too are already flying ~25% higher today. Overall, the Street has a $456.70 consensus price target on Argenx alongside a Strong Buy consensus rating.  

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Argenx, Zai Lab Soar on Promising Data in CIDP
News On DemandStay up-to-date on market-moving news with a feed made just for youGet the App

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles